Canaccord Genuity Raises Price Target on BioMarin Pharma (BMRN) Following BMN-111 Data

Pre-Open Stock Movers 06/18: (LMNS) (DGLY) (BMRN) Higher; (HERO) (RATE) (ORCL) Lower (more...)

Hercules Offshore, Inc. (Nasdaq: HERO) 64.3% LOWER; entered into a Restructuring Support Agreement with a steering group of its senior noteholders, to file under Chapter 11.

Bankrate (NYSE:... More

BioMarin's (BMRN) Price Target Raised to $156 at Deutsche Bank

Deutsche Bank maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and raised its price target to $156.00 (from $140.00). The change follows positive phase 2 BMN-111 data in achondroplasia.

Analyst Robyn Karnauskas said, "BioMarins achondroplasia drug, BMN-111 (now called vosoritide) worked in phase 2, showing a 50% improvement in mean annualized growth velocity of... More

BioMarin (BMRN) PT Lifted to 'Street High' $170 at SunTrust Amid Growing Confidence in Dwarfism Drug BMN 111

SunTrust Robinson Humphrey analyst Salveen Richter reiterated a Buy and boosted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $170.00 (from $151.00) amid growing confidence in BMN 111 following data.

"BMRN's BMN111 Phase II data in achondroplasia, most common form of dwarfism, reflect a... More

BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC

RBC Capital maintained an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and raised its price target to $145.00 (from $125.00). Yesterday BioMarin reported positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide) in children with achondroplasia, the most common form... More

BioMarin Pharmaceutical (BMRN) PT Raised to $147 at Piper Jaffray Following Positive BMN-111 Update

Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and bumped his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $147.00 (from $123.00) following data from the long awaited P2 trial of BMN111 (vosoritide) in children with achondroplasia.

Schimmer commented, "Our... More

BioMarin (BMRN) PT Raised to $143 at Leerink Partners as BMN-111 Meets Primary Endpoint

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and bumped his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $143.00 (from $136.00) reported positive top-line results for the BMN-111 (vosoritide) Ph II trial in Achondroplasia (ACH), meeting the primary endpoint with a 50% increase in annualized... More

After-Hours Stock Movers 06/17: (PIR) (BMRN) (JUNO) Higher; (RATE) (ONVO) (ORCL) Lower (more...)

Bankrate (NYSE: RATE) 15% LOWER; reported Q1 EPS of $0.19, in-line with the analyst estimate of $0.19. Revenue for the quarter came in at $141.5 million versus the consensus estimate of $137.98 million. Bankrate also announced the results of the internal review conducted by the Audit Committee of the Bankrate Board of Directors and the restatement of its financial statements for fiscal years 2011, 2012 and 2013, the fiscal quarters within those years, and the fiscal quarters ended March 31, 2014 and June 30, 2014.

Organovo (NYSE: ONVO)... More

BioMarin Pharma (BMRN) Issues Positive Update from BMN 111 Phase 2 Proof-of-Concept, Dose Finding Study

BioMarin Pharma (NASDAQ: BMRN) announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide), an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia. Achondroplasia is the most common form of human dwarfism. Vosoritide has Orphan designation in both the United States and Europe.

Phase 2 Results and Safety Summary of First Six Months

Data from the 26 children participating in the Phase 2 study demonstrated a favorable safety profile and efficacy at the 15 micrograms/kilogram/daily dose. The 10 children in Cohort 3 treated with 15 micrograms per kilogram per... More